EGFR-TKI With Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism
Status:
Unknown status
Trial end date:
2018-07-01
Target enrollment:
Participant gender:
Summary
BIM deletion polymorphism might be associated with a poor clinical response to EGFR-TKIs in
patients who had NSCLC with EGFR mutations. In the study, the investigators want to use
EGFR-TKI with chemotherapy as first line treatment in stage IIIB/IV NSCLC patients with both
EGFR mutation and BIM deletion polymorphism.